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DeOBJECTIVES The aim of this study was to investigate the association between high on-treatment platelet reactivity
(HPR) and the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SS)
for risk prediction of major adverse cardiovascular events (MACE) in patients with non–ST-segment elevation acute
coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI).
BACKGROUND Platelet function testing may be used to optimize antiplatelet therapy in high-risk patients,
but identiﬁcation of this category of patients remains challenging.
METHODS The GEPRESS (Gene Polymorphism, Platelet Reactivity, and the Syntax Score) study was a prospective,
multicenter, observational study enrolling 1,053 patients with NSTEACS undergoing PCI and treated with clopidogrel.
The platelet reactivity index (PRI) was measured at 3 time points: before PCI, at hospital discharge, and 1 month after PCI.
Genetic variants of clopidogrel metabolism were determined in 750 patients. Patients were stratiﬁed by the presence of
HPR (PRI >50%) and by tertile of the SS (upper SS tertile $15). The primary objective of this study was the risk of MACE
in the period between 1 month and 1 year.
RESULTS Between 1 month and 1 year, 1-month HPR was an independent predictor of MACE in patients with an SS $15,
but not in those with an SS <15, displaying a 5-fold increase in event rates (10.4% vs. 2.5%; p < 0.0001). CYP2C19*2 was
the only single nucleotide polymorphism associated with HPR, but it was not associated with MACE. Although there was a
signiﬁcant variability in the PRI across the 1-month period, predischarge HPR and SS effectively stratiﬁed the risk of
subsequent MACE up to 1-year follow-up.
CONCLUSIONS In clopidogrel-treated patients with NSTEACS undergoing PCI, HPR was independently associated with
an increased risk of MACE only in the presence of a high SS. (J Am Coll Cardiol Intv 2014;7:1117–27) © 2014 by the
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ABBR EV I A T I ON S
AND ACRONYMS
BARC = Bleeding Academic
Research Consortium
CI = conﬁdence interval
HPR = high on-treatment
platelet reactivity
IDI = integrated discrimination
improvement
LVEF = left ventricular ejection
fraction
MACE = major adverse
cardiovascular event(s)






OR = odds ratio
PRI = platelet reactivity index
ROC = receiver-operating
characteristic
SNP = single nucleotide
polymorphism
SS = SYNTAX score
VASP = vasodilator-stimulated
phosphoprotein
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1118H igh on-treatment platelet reac-tivity (HPR) has emerged as a riskfactor for stent thrombosis and
major adverse cardiovascular events (MACE)
in patients who receive clopidogrel after
percutaneous coronary intervention (PCI)
(1). Multiple factors can contribute to these
pharmacodynamic ﬁndings (2). In particular,
genetic factors have been shown to be associ-
ated with poor responsiveness to clopidogrel
(3), but their impact on the risk of MACE is
controversial (4,5). Moreover, the low posi-
tive predictive value of HPR and the absence
of large-scale randomized clinical trials sup-
porting the use of platelet function testing
question the utility of routine assessment of
platelet reactivity in patients undergoing
PCI (6). Accordingly, current guidelines do
not endorse routine use of platelet function
testing, but they suggest that in selected
patients at high risk of a poor outcome after
PCI, platelet function testing can be imple-
mented to optimize antiplatelet therapy (7).
However, identiﬁcation of these patients
remains challenging.
Prospectively developed for the SYNTAX
(Synergy Between Percutaneous CoronaryIntervention With Taxus and Cardiac Surgery) trial
(8), the SYNTAX score (SS) has been shown to be
associated with an increased risk of mortality,
myocardial infarction (MI), and stent thrombosis in
patients with non–ST-segment elevation acute coro-
nary syndromes (NSTEACS) undergoing PCI (9). The
relationship between the SS and the presence of HPR
for the risk of MACE, however, has never been
investigated. Other unsolved dilemmas include the
relative prognostic value of platelet function testing
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reactivity over time, and the existence of a thera-
peutic window for platelet reactivity. On this
background, in the present study, we sought to
investigate the following: 1) the association between
platelet reactivity and the SS for the risk of MACE in
patients with NSTEACS undergoing PCI treated with
clopidogrel; 2) the association between genetic vari-
ants involved in clopidogrel-mediated platelet effects
and the risk of MACE; 3) the incremental prognostic
value of the platelet reactivity measured at several
time points; and 4) the existence of a therapeutic
window of platelet reactivity, which could be associ-
ated with a low risk of both ischemic and bleeding
events.
METHODS
PATIENTS AND STUDY DESIGN. The GEPRESS (Gene
Polymorphism, Platelet Reactivity, and the Syntax
Score) study is a prospective, multicenter study
designed to determine the impact of platelet reac-
tivity, the SS, and the presence of several genetic
variants modulating clopidogrel-mediated effects on
the risk of ischemic and bleeding events in patients
with NSTEACS undergoing PCI and treated with clo-
pidogrel. Patients were eligible for enrollment if they
had NSTEACS and at least 1 stenosis >50% requiring
PCI. Patients were stratiﬁed by the presence of HPR
and tertiles of the SS. HPR was deﬁned using the
vasodilator-stimulated phosphoprotein (VASP) assay
as described in the following. SS was determined by
experienced core angiographic laboratory technicians
(Cardiovascular Research Foundation, New York,
New York) blinded to clinical outcomes. For the pur-
pose of the study, patients in the upper SS tertile
(SS $15) were compared with patients in the mid or
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FIGURE 1 Flow Diagram of the Study
Platelet reactivity index (PRI) was determined before percutaneous coronary intervention
(PCI), at hospital discharge, and 1 month after PCI.
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1119Exclusion criteria were allergy or intolerance to
aspirin and clopidogrel, need for concomitant oral
anticoagulant therapy, cardiogenic shock, any con-
traindication or inability to comply with dual-
antiplatelet therapy for 1 year, treatment with
prasugrel or ticagrelor, and major comorbidities
associated with life expectancy <1 year. The study
was approved by the local ethics committee at each
participating center, and all patients provided written
informed consent.
PLATELET FUNCTION TESTING. Platelet reactivity
was measured using the VASP assay (Biocytex,
Marseille, France) using ﬂow cytometric technique as
previously described (10), and it was expressed as
platelet reactivity index (PRI). HPR was deﬁned as a
PRI >50% as previously reported to be associated
with ischemic recurrences and in agreement with
expert consensus (11). The VASP assay was used to
measure platelet reactivity because results are not
affected by the use of glycoprotein IIb/IIIa inhibitors,
which are commonly used in patients with NSTEACS,
particularly among enrolling centers in this study.
The PRI was determined at 3 time points: before PCI,
at hospital discharge, and at 1 month after PCI. Clin-
ical events were then correlated with the closest PRI
determination performed before the event, so that
periprocedural events were correlated with the PRI
measured before PCI, events between discharge and
1 month with the PRI measured at hospital discharge,
and events between 1 month and 1 year with the PRI
determined at 1 month.
OBJECTIVE AND DEFINITIONS. The primary objec-
tive of this study was to investigate the association
between 1-month HPR and the SS for the risk of MACE
(cardiac mortality, MI, and stent thrombosis) in the
period between 1 month and 1 year. The rationale
for considering 1-month HPR was that previous
investigations have shown that in clopidogrel-treated
patients undergoing PCI, platelet reactivity improves
over the course of the ﬁrst week of treatment and
HPR rates may be spuriously high if determined too
early (12). Secondary endpoints included all-cause
death, cardiac death, MI, cardiac death/MI, stent
thrombosis, and bleeding determined in the peri-
procedural period, between hospital discharge and
1 month, and between 1 month and 1 year. The impact
of genetic variants of clopidogrel metabolism on the
risk of MACE was determined as well. NSTEACS
included unstable angina and non–ST-segment
elevation myocardial infarction (NSTEMI). Unstable
angina was deﬁned as the presence of typical chest
pain at rest with an electrocardiographic documen-
tation of ischemia, whereas NSTEMI was deﬁnedas the presence of typical chest pain associated with
an increase of troponin levels. Stent thrombosis
was deﬁned according to the Academic Research
Consortium deﬁnition (13). Bleeding was deﬁned
according to the Bleeding Academic Research Con-
sortium (BARC) deﬁnition (14). Net adverse clinical
events were deﬁned as the occurrence of MACE and
BARC bleeding. The other deﬁnitions of the study are
reported in Online Table 1.
PERCUTANEOUS CORONARY INTERVENT ION .
PCI was performed according to the standard of care.
The choice of anticoagulant (unfractionated heparin,
low molecular weight heparin, bivalirudin), use of
glycoprotein IIb/IIIa inhibitors, as well as the type of
stent was left to the operator’s discretion. All patients
were treated with 250 mg aspirin at clinical presen-
tation. Patients who were not receiving long-term
clopidogrel therapy ($7 days) at the time of PCI
were treated with a 300-mg or 600-mg clopidogrel
loading dose. After PCI, patients were treated with
aspirin 160 mg/day indeﬁnitely, and clopidogrel
75 mg/day was recommended for 1 year.
GENOTYPIC ANALYSIS. A total of 14 single nucleotide
polymorphisms (SNPs) potentially implicated in
modulating clopidogrel-mediated effects were deter-
mined. DNA was extracted from whole blood by an
automated puriﬁcation system (MagCore HF16, RBC
Bioscience Corp., Taiwan). The MassARRAY Assay
Design 4.0 software (Sequenom, Inc., San Diego, Cali-
fornia) was used to design 2 multiplex polymerase
chain reactions for the SNP analysis. Genotyping
TABLE 1 Clinical Characteristics of Patients Included in the Study
Variable Whole Cohort Genetic Cohort p Value
Age, yrs 67 (58–77) 67 (58–77) 0.57
Male 76.1 (803/1,056) 75.3 (565/750) 0.77
Body mass index, kg/m2 26.6 (24–29) 28.0 (24–30) 0.02
Hypercholesterolemia 56.7 (598/1,056) 58.8 (441/750) 0.38
Hypertension 72.0 (760/1,056) 72.4 (543/750) 0.88
Smoking 49.8 (525/1,056) 52.9 (397/750) 0.19
History of coronary artery disease 30.2 (319/1,056) 31.6 (237/750) 0.56
Diabetes mellitus 26.8 (283/1,056) 27.9 (209/750) 0.65
Peripheral vascular disease 8.0 (84/1,056) 9.1 (68/750) 0.45
Renal dysfunction 11.7 (123/1,056) 12.9 (97/750) 0.45
Chronic obstructive pulmonary disease 9.7 (102/1,056) 10.1 (76/750) 0.80
Unstable angina, % 39.5 (417/1,056) 36.4 (273/750) 0.20
NSTEMI 60.5 (639/1,056) 63.6 (477/750) 0.20
Previous myocardial infarction 24.8 (262/1,056) 28.8 (216/750) 0.07
Previous PCI 23.6 (249/1,056) 25.5 (191/750) 0.39
Previous CABG 7.1 (75/1,056) 8.0 (60/750) 0.53
Left ventricular ejection fraction 55.0 (48–60) 51.2 (48–60) 0.65
Preprocedural clopidogrel treatment
Chronic therapy* 9.0 (74/822) 10.0 (51/508) 0.59
Bolus 300 mg #1 h before PCI 21.9 (180/822) 27.8 (141/508) 0.02
Bolus 300 mg >1 h before PCI 29.6 (243/822) 29.5 (150/508) 0.99
Time from bolus to PCI, h 25.0 (16.0–48.0) 35.5 (22.0–49.5)
Bolus 600 mg #1 h before PCI 18.4 (151/822) 24.2 (123/508) 0.01
Bolus 600 mg >1 h before PCI 11.1 (91/822) 2.2 (11/508) <0.001
Time from bolus to PCI, h 12.0 (4.0–18.0) 24.0 (8.0–48.0)
Long-term therapy or 600 mg
bolus >12 h
13.4 (110/822) 11.4 (58/508) 0.34
Therapy at discharge
Aspirin 99.2 (1,048/1,056) 99.6 (747/750) 0.51
Clopidogrel 99.7 (1,053/1,056) 100 (750/750) 0.38
Beta-blocker 78.7 (830/1,056) 78.1 (586/750) 0.86
ACEI 73.2 (772/1,056) 54.0 (570/750) 0.18
Statin 86.7 (915/1,056) 60.5 (638/750) 0.38
Nitroderivate 16.9 (178/1,056) 11.5 (121/750) 0.73
Calcium channel blocker 11.9 (126/1,056) 9.2 (97/750) 0.57
Angiotensin receptors blocker 10.5 (111/1,056) 7.4 (78/750) 0.99
Diuretic agent 16.9 (178/1,056) 13.8 (146/750) 0.17
Proton pump inhibitor 53.4 (563/1,056) 54.2 (407/750) 0.73
Ranitidine 33.2 (350/1,056) 31.8 (239/750) 0.60
Values are median (interquartile range) or % (n/N). *Clopidogrel treatment for at least 7 days before the
procedure.
ACEI ¼ angiotensin-converting enzyme inhibitor; CABG ¼ coronary artery bypass graft; NSTEMI ¼
non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention.
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1120was performed using iPLEX Gold technology, as pre-
viously described (15), and MassARRAY high-
throughput DNA analysis with matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrom-
etry, according to manufacturer’s instructions. Hardy-
Weinberg equilibrium was tested in all patients
included in the genetic study. Participation in the ge-
netic substudy of the GEPRESS trial was voluntary for
sites and patients. Collection and genetic analysis of
samples was subject to informed consent from allpatients and to approval by the local ethics committee.
The consent was separate from that of the main study.
SAMPLE SIZE AND STATISTICAL ANALYSIS. As the
relationship between the PRI and the SS for the risk of
MACE has never been investigated, to determine the
sample size of the study, we based our assumptions
on the association between PRI and the risk of MACE.
Assuming an area under the receiver-operating char-
acteristic (ROC) curve of 0.65, with a null hypothesis
set at 0.50, a ¼ 0.05, b ¼ 0.10, and an incidence of
MACE of 5% between 1 month and 1 year, a sample of
840 patients would be required to show an associa-
tion between PRI and MACE. Considering a patient
drop-out rate of 10%, we aimed to recruit w1,000
patients. Continuous data are presented as median
and interquartile range and were compared by the
Kruskal-Wallis 1-way analysis of variance. The Dunn
test was used to determine signiﬁcant differences for
multiple comparisons. Categorical variables were
compared by the chi-square or Fisher exact test, as
appropriate. Time-to-event outcomes were analyzed
by Kaplan-Meier analysis, and differences were
compared using the log-rank test. ROC curves were
generated to determine the discriminative power of
the PRI and the SS for the risk of ischemic and
bleeding events. The optimal cutoff point was calcu-
lated by determining the value with the greatest sum
of sensitivity and speciﬁcity. Stepwise multivariable
Cox regression analyses were performed to assess
independent predictors of MACE between 1 month
and 1 year. Several multivariable models were con-
structed to determine the additive prognostic value
of the PRI and the SS after adjusting for main con-
founders known to have an impact on the risk of
MACE, as suggested by previous studies (16,17). The
prognostic accuracy of each model was assessed by
the C-statistic, the integrated discrimination
improvement (IDI), and the net reclassiﬁcation
improvement (18,19). The following variables were
included in the stepwise multivariable models: clin-
ical presentation with NSTEMI (positive troponin
levels), PRI, SS, renal dysfunction, age, and diabetes.
The same analyses were repeated in the cohort of
patients who had the left ventricular ejection fraction
(LVEF) determined or who underwent the genetic
screening for loss-of-function or gain-of-function
alleles involved in clopidogrel absorption or meta-
bolism. SNPs were tested for their association with
HPR by logistic regression analysis using a stepwise
multivariable model after adjusting for clinical char-
acteristics. Other variables included in the model
were age, sex, diabetes, smoking, renal dysfunction,
therapy with proton pump inhibitors, body mass
FIGURE 2 Proportion of Patients With a PRI >50% Measured
Before PCI, at Hospital Discharge, and 1 Month After PCI
The proportion of patients with PRI>50% was 69% before
PCI, 49% at hospital discharge, and 41% 1 month after PCI.
Abbreviations as in Table 1.
TABLE 2 Association Between Genetic Variants Modulating Clopidogrel-Mediated
Effects and Platelet Reactivity Index Determined at 1 Month
SNP Patients PRI, % p Value PRI >50% p Value
CYP2C19*2, 681 G>A <0.001 <0.001
GG 69.2 (496/717) 44 (30–59) 39.3 (195/496)
GA 27.9 (200/717) 52 (40–65) 56.0 (112/200)
AA 2.9 (21/717) 66 (54–73) 81.0 (16/21)
CYP2C19*3, 636 G>A 0.12 0.39
GG 99.7 (715/717) 47 (32–61) 44.9 (321/715)
GA 0.3 (2/717) NA 100 (2/2)
AA 0.0 (0/717) NA NA
CYP2C19*4, 1 A>G 0.50 0.62
AA 99.0 (710/717) 48 (32–61) 45.2 (321/710)
GA 1.0 (7/717) 41 (24–59) 28.6 (2/7)
GG 0.0 (0/717) NA NA
CYP2C19*17, 806 C>T 0.04 0.16
CC 63.7 (456/716) 49 (34–62) 47.4 (216/456)
TC 33.2 (238/716) 46 (32–60) 41.6 (99/238)
TT 3.1 (22/716) 35 (17–55) 31.8 (7/22)
CYP3A4*1G, intron 10C>T 0.44 0.87
CC 76.4 (548/717) 48 (32–62) 45.4 (249/548)
TC 22.5 (161/717) 46 (31-60) 43.5 (70/161)
TT 1.1 (8/717) 51% (49-67) 50.0 (4/8)
CYP3A4*1B, 3924 A>G 0.72 0.67
AA 93.2 (668/717) 48 (32–61) 44.8 (299/668)
GA 6.8 (49/717) 48 (31–64) 49.0 (24/49)
GG 0.0% (0/717) NA NA
CYP3A5*3, 6986 G>A 0.47 0.98
GG 85.9 (616/717) 48 (32–61) 45.0 (277/616)
GA 13.8 (99/717) 48 (34–62) 45.5 (45/99)
AA 0.3 (2/717) NA 50.0 (1/2)
ABCB1, 3435 C>T 0.08 0.08
CC 26.4 (189/716) 42 (31–61) 43.9 (83/189)
TC 52.7 (377/716) 47 (32–60) 42.7 (161/377)
TT 20.9 (150/716) 51 (37–62) 53.3 (80/150)
IRS-1, 227497991 A>G 0.11 0.33
AA 90.5 (649/717) 47 (32–61) 44.3 (288/649)
AG 9.4 (67/717) 51 (40–63) 50.7 (34/67)
GG 0.1 (1/717) NA 100 (1/1)
IRS-1, 227382808 G>C 0.78 0.28
GG 80.5 (575/714) 48 (32–61) 46.2 (266/575)
GC 17.9 (128/714) 46 (34–59) 39.1 (50/128)
CC 1.5 (11/714) 47 (38–56) 36.4 (4/11)
PON1, 163 A>T 0.21 0.34
AA 39.2 (281/717) 49 (34–61) 48.0 (135/281)
TA 45.3 (325/717) 46 (30–61) 42.2 (137/325)
TT 15.5 (111/717) 48 (33–62) 45.9 (51/111)
PON1, 575 A>G 0.72 0.46
AA 47.8 (343/717) 47 (32–60) 42.9 (147/343)
GA 43.1 (309/717) 48 (32–62) 47.6 (147/309)
GG 9.1 (65/717) 48 (31–60) 43.1 (28/65)
ITGB3, 196 T>C 0.76 0.78
TT 67 (479/717) 47 (32–61) 44 (211/479)
TC 31 (224/717) 49 (32–61) 46 (104/224)
CC 2 (14/717) 50 (36–63) 50 (7/14)
Values are % (n/N) or median (interquartile range).
NA ¼ not available; PRI ¼ platelet reactivity index; SNP ¼ single nucleotide polymorphism.
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1121index, NSTEMI at hospital admission, LVEF, number
of vessel disease, and the SS. Statistical analyses were
performed using the Statistical Package for Social
Sciences for Windows, version 12.0, software (SPSS,
Inc., Chicago, Illinois). Values p<0.05were considered
statistically signiﬁcant.
RESULTS
STUDY POPULATION. The ﬂow diagram of the study
is shown in Figure 1. A total of 1,056 NSTEACS patients
provided written informed consent; 3 patients with-
drew consent before hospital discharge, and therefore
1,053 patients were ﬁnally included in the study.
Follow-up rates were 100% at 30 days and 99% at
1 year. All patients were compliant with dual-
antiplatelet therapy at 30 days, whereas 5 patients
interrupted clopidogrel between 1 month and 1 year
(2 patients for personal decision and 3 because of
unplanned noncardiac surgery). These patients
were excluded from the landmark analysis between
30 days and 1 year. Clinical and angiographic char-
acteristics of patients included in the study are shown
in Table 1 and Online Table 2, respectively. A total of
366 patients were in the lower SS tertile (SS #8), 309
in the intermediate tertile (8<SS<15), and 365 in the
upper tertile (SS $15).
GENOTYPIC AND PHENOTYPIC ANALYSIS. PRI values
signiﬁcantly changed from baseline to 1-month follow
up (p < 0.001). Median (interquartile range) PRI
values were 63% (44% to 76%) at baseline, 50% (34%
to 66%) at hospital discharge, and 46% (32% to 60%)
at 1 month (p < 0.05 for all comparisons). As shown
TABLE 3 Clinical Outcomes of Patients Stratiﬁed by the PRI
PRI >50% PRI #50% p Value
Clinical outcomes between PCI and hospital discharge
(stratiﬁed by pre-procedural PRI)*
MACE‡ 3.1 (22) 3.4 (11) 0.91
Death 0.0 (0) 0.0 (0) NA
Cardiac death 0.0 (0) 0.0 (0) NA
Cardiac death/myocardial infarction 2.9 (21) 3.4 (11) 0.81
Myocardial infarction 2.9 (21) 3.4 (11) 0.81
Stent thrombosis 0.1 (1) 0.3 (1) 0.86
Any BARC bleeding 0.3 (2) 0.3 (2) 0.59
BARC $2 0.0 (0) 0.0 (1) 0.68
Clinical outcomes between discharge and 30 days
(stratiﬁed by PRI at hospital discharge)*
MACE 1.2 (6) 0.8 (4) 0.71
Death 0.6 (3) 0.9 (5) 0.76
Cardiac death 0.6 (3) 0.4 (2) 0.97
Cardiac death/myocardial infarction 1.0 (5) 0.8 (4) 0.96
Myocardial infarction 0.8 (4) 0.4 (2) 0.65
Stent thrombosis 0.8 (4) 0.0 (0) 0.13
Any BARC bleeding 0.4 (2) 1.2 (6) 0.31
BARC $2 0.0 (0) 0.4 (2) 0.49
Clinical outcomes between discharge and 1 year
(stratiﬁed by PRI at hospital discharge)†
MACE 5.6 (28) 2.0 (10) 0.002
Death 3.3 (16) 2.4 (17) 0.93
Cardiac death 2.3 (11) 0.8 (5) 0.11
Cardiac death/myocardial infarction 5.8 (28) 2.0 (10) 0.002
Myocardial infarction 4.1 (20) 1.0 (5) 0.002
Stent thrombosis 1.9 (9) 0.2 (1) 0.01
Any BARC bleeding 3.1 (16) 5.0 (25) 0.18
BARC $2 1.1 (5) 3.7 (18) 0.007
Clinical outcomes between 1 month and 1 yr
(stratiﬁed by 30-day PRI)†
MACE 5.6 (23) 1.6 (9) 0.0003
Death 3.2 (13) 1.9 (12) 0.27
Cardiac death 2.2 (9) 0.5 (3) 0.02
Cardiac death/myocardial infarction 5.6 (23) 1.4 (8) 0.002
Myocardial infarction 3.7 (15) 0.9 (5) 0.002
Stent thrombosis 1.2 (5) 0.2 (1) 0.03
Any BARC bleeding 1.7 (7) 4.5 (26) 0.02
BARC $2 0.3 (1) 3.5 (20) 0.0006
Values are % (n). *p values determined by chi-square statistic. †Estimates of risk are determined by Kaplan-Meier
analyses and compared with the log-rank test. ‡Includes cardiac death, myocardial infarction, and stent
thrombosis.
BARC ¼ Bleeding Academic Research Consortium; MACE ¼ major adverse cardiovascular events; other
abbreviations as in Tables 1 and 2.
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1122in Figure 2, the percentage of patients with HPR was
69% before PCI, 49% at hospital discharge, and 41% at
1 month. The association between genetic variants
modulating clopidogrel effects and 1-month PRI
values is shown in Table 2. All SNPs tested in the re-
gion of interest were in Hardy-Weinberg equilibrium
(p > 0.05) except for CYP2C19*5. Among the SNPs
tested, only CYP2C19*2 was signiﬁcantly asso-
ciated with HPR. Independent predictors of HPR at
1 month were CYP2C19*2 (odds ratio [OR]: 2.16, 95%conﬁdence interval [CI]: 1.56 to 3.00; p < 0.0001),
diabetes mellitus (OR: 1.41, 95% CI: 1.01 to 1.99; p ¼
0.045), and smoking (OR: 0.68, 95% CI: 0.50 to 0.93;
p ¼ 0.01). Therapy with proton pump inhibitors had
borderline statistical signiﬁcance (OR: 1.32, 95% CI:
0.97 to 1.78; p ¼ 0.07).
CLINICAL OUTCOMES. Clinical outcomes stratiﬁed
by HPR are shown in Table 3. Of note, no association
was apparent between the presence of preprocedural
HPR and the risk of periprocedural MACE or between
HPR at hospital discharge and the risk of MACE
between hospital discharge and 30-day follow up. In
contrast, in the period between 1 month and 1 year,
patients with either HPR at 1 month (Figure 3A), or
with an SS $15 (Figure 3B) had signiﬁcantly higher
rates of MACE compared with patients without HPR
or an SS <15, respectively. Moreover, as shown in
Table 3, patients without HPR had signiﬁcantly higher
rates of bleeding than patients with HPR. There was
no signiﬁcant difference between the discriminatory
power of PRI measured at 1 month compared with PRI
measured at hospital discharge for events occurring
between 1 month and 1 year, although C-statistic
values were slightly better for PRI measured at
1 month both for MACE (C-statistic, 0.63 vs. 0.60,
respectively; p ¼ 0.61) and bleeding (C-statistic, 0.73
vs. 0.66, respectively; p ¼ 0.23). Clinical outcomes
stratiﬁed by HPR and the SS are shown in Table 4.
As shown in Figure 3C, in the period between
1 month and 1 year, the risk of MACE was 10.4% in
patients with HPR and an SS $15 and 2.5% in those
with HPR but an SS <15 (p < 0.0001). Similarly, pa-
tients with HPR at hospital discharge and an SS $15
displayed the highest risk of MACE, cardiac mortality,
MI, and stent thrombosis in the period between hos-
pital discharge and 1 year compared with other pa-
tients. Of note, no association was apparent between
the risk of MACE at any time point and CYP2C19*2
(Online Table 3).
MULTIVARIABLE ANALYSES. Multivariable analyses
with or without HPR and the SS are shown in Table 5
(models 1 through 4). Age and diabetes mellitus
were the only clinical variables associated with an
increased risk of MACE in the period between 1 month
and 1 year (model 1). The effect size of HPR and the SS
are shown in models 2 and 3. As shown in model 4,
after adjusting for age and diabetes mellitus, the as-
sociation between HPR and an SS $15 (OR: 12.2, 95%
CI: 3.5 to 42.7), but not between HPR and an SS <15
(OR: 3.33, 95% CI: 0.82 to 13.53) was an independent
predictor of MACE. Similarly, HPR was an indepen-
dent predictor of MACE in patients with an SS $15
(OR: 3.78, 95% CI: 1.03 to 13.83, p ¼ 0.04), but not
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1123in those with an SS <15 (OR: 2.91, 95% CI: 0.70 to
11.92, p ¼ 0.14). However, no signiﬁcant interaction
was apparent between the 2 variables (p ¼ 0.87).
Performance measures in models with or without
HPR and the SS are shown in Online Table 4.
Including HPR (model 2) improved the prognostic
performance of the multivariable models with only
age and diabetes mellitus (model 1), but the model
including both HPR and the SS (model 3) had the best
prognostication performances, with a C-statistic of
0.81, a net reclassiﬁcation improvement of 18%, and
an IDI of 2.3% compared with the model including
age, diabetes mellitus, and HPR (model 2). Results did
not signiﬁcantly change when we considered the
cohort of patients who had an LVEF or the genotype
determined. There was no independent relationship
between any SNPs and the risk of MACE.
THERAPEUTIC WINDOW. The optimal cutoff values
determined by ROC analyses for the risk of MACE
(PRI >51%) or BARC bleeding $2 (PRI #40%) in the
period between 1 month and 1 year were used to
stratify patients into 3 groups: group 1 had a PRI
#40%, group 2 had a PRI between 40% and 51%, and
group 3 had a PRI >51%. As shown in Figure 4, the
incidence of net adverse clinical events was 5.8% in
group 1, 3.2% in group 2, and 6.2% in group 3 (p¼ 0.37).FIGURE 3 Kaplan-Meier Analysis Showing Survival Free From
Major Adverse Cardiac Events
Survival free from major adverse cardiac events (MACE) in patients stratiﬁed by the
platelet reactivity index (PRI) (A), the SYNTAX score (SS) (B), and both PRI and SS (C).
Patients were stratiﬁed by tertiles of SS, and then the upper tertile of SS ($15)
was compared with pooled mid and lower SS tertiles.DISCUSSION
This is the ﬁrst study investigating the relative
impact of HPR, SS, and genetic variants modulating
clopidogrel effects on the risk of MACE in patients
with NSTEACS undergoing PCI. The main ﬁndings
of this study are as follows: 1) after adjusting for
main confounders, HPR determined at 1 month
was associated with signiﬁcantly higher rates of
MACE between 1 month and 1 year in patients in
the upper SS tertile, but not in those in the inter-
mediate or lower tertile; 2) although CYP2C19*2 was
the only SNP associated with HPR, it was not inde-
pendently associated with the risk of MACE; 3)
although platelet reactivity signiﬁcantly varied
across the 1-month period, there was no signiﬁcant
difference between PRI measured at 1 month and PRI
measured at hospital discharge for risk prediction of
both ischemic and bleeding events in the period be-
tween 1 month and 1 year; and 4) a therapeutic
window of PRI in the 40% to 51% range deﬁned a
group of patients with a trend toward a lower risk of
net clinical outcome.
Several observational studies have consistently
reported an association between HPR and the risk
of stent thrombosis and MACE (1,20), suggesting








SS $15 p Value
Periprocedural outcomes
(stratiﬁed by pre-procedural PRI)*
MACE 3.9 (10) 2.4 (11) 4.3 (9) 1.9 (2) 0.42
Death 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) NA
Cardiac death 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) NA
Cardiac death/myocardial infarction 3.9 (10) 2.4 (11) 4.3 (9) 1.9 (2) 0.42
Myocardial infarction 3.9 (10) 2.4 (11) 4.3 (9) 1.9 (2) 0.42
Stent thrombosis 0.0 (0) 0.0 (0) 0.0 (0) 0.9 (1) NA
Any BARC bleeding 0.8 (2) 0.0 (0) 0.0 (0) 1.9 (2) 0.02
BARC $2 0.0 (0) 0.0 (0) 0.0 (0) 0.9 (1) 0.04
Outcomes between hospital discharge and 30 days
(stratiﬁed by PRI at hospital discharge)*
MACE 2.5 (5) 0.0 (0) 0.8 (3) 0.7 (1) 0.04
Death 1.5 (3) 0.0 (0) 1.1 (4) 0.7 (1) 0.26
Cardiac death 1.5 (3) 0.0 (0) 0.3 (1) 0.7 (1) 0.11
Cardiac death/myocardial infarction 2.5 (5) 0.0 (0) 0.8 (3) 0.7 (1) 0.04
Myocardial infarction 2.0 (4) 0.0 (0) 0.6 (2) 0.0 (0) 0.03
Stent thrombosis 2.0 (4) 0.0 (0) 0.0 (0) 0.0 (0) 0.001
Any BARC bleeding 0.0 (0) 0.7 (2) 1.4 (5) 0.7 (1) 0.36
BARC $2 0.0 (0) 0.0 (0) 0.6 (2) 0.0 (0) 0.32
Outcomes between hospital discharge and 1 year
(stratiﬁed by PRI at hospital discharge)†
MACE 10.8 (22) 2.1 (6) 1.7 (6) 2.8 (4) <0.0001
Death 6.6 (13) 1.1 (3) 2.2 (9) 5.6 (8) 0.003
Cardiac death 4.1 (8) 1.1 (3) 0.6 (2) 1.4 (3) 0.01
Cardiac death/myocardial infarction 11.3 (22) 2.1 (6) 1.7 (6) 2.8 (4) <0.0001
Myocardial infarction 8.8 (17) 1.1 (3) 1.1 (4) 0.7 (1) <0.0001
Stent thrombosis 4.2 (8) 0.4 (1) 0.0 (0) 0.7 (1) <0.0001
Any BARC bleeding 3.2 (6) 3.2 (10) 5.3 (19) 4.2 (6) 0.55
BARC $2 1.1 (2) 1.1 (3) 3.7 (13) 3.5 (5) 0.07
Outcomes between 30 days and 1 yr
(stratiﬁed by 30-day PRI)†
MACE 10.4 (17) 2.5 (6) 0.8 (3) 3.4 (6) <0.0001
Death 4.5 (8) 2.1 (5) 0.7 (3) 4.9 (9) 0.005
Cardiac death 3.7 (6) 1.2 (3) 0.3 (1) 1.1 (2) 0.02
Cardiac death/myocardial infarction 10.4 (17) 2.5 (6) 0.8 (3) 2.8 (5) <0.001
Myocardial infarction 7.5 (12) 1.3 (3) 0.5 (2) 1.7 (3) <0.001
Stent thrombosis 2.5 (4) 0.4 (1) 0.0 (0) 0.6 (1) 0.02
Any BARC bleeding 1.9 (3) 1.7 (4) 4.5 (18) 4.5 (8) 0.14
BARC $2 0.0 (0) 0.4 (1) 3.3 (13) 4.0 (7) 0.008
Values are % (n). *p Values are determined by chi-square statistic. †Estimates of risk are determined by Kaplan-Meier analyses and are compared with the log rank test.
SS ¼ SYNTAX score; other abbreviations as in Tables 2 and 3.
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1124that platelet function testing could be used to opti-
mize antiplatelet therapy on the basis of platelet
responsiveness to clopidogrel. However, no such
evidence has been provided so far by large-scale
interventional studies, which failed to demonstrate
the utility of platelet function testing to guide anti-
platelet therapy after PCI (6). Accordingly, guidelines
do not endorse the routine use of platelet function
testing, with the possible exception of high-risk pa-
tients who are expected to have a poor outcome after
PCI (7). However, identifying this category of patients
remains challenging.The GEPRESS study is the ﬁrst to identify a
subset of patients in whom platelet function testing
may provide incremental prognostic value. Patients
with HPR and a high SS displayed a 5-fold
higher risk of MACE compared with patients with
HPR and a low SS, and in the multivariable analysis,
HPR was independently associated with increased
rates of MACE in patients in the upper tertile of
SS, but not in those in the intermediate or lower
tertiles. Moreover, adding the SS in the multivari-
able model, which already included conventional
risk factors and HPR, was associated with a net
FIGURE 4 Net Clinical Outcome Including Ischemic and
Bleeding Events in Patients Stratiﬁed According to
Clopidogrel Responsiveness
A therapeutic window of PRI was identiﬁed that deﬁned patients
at lower risk of both ischemic and bleeding events. MACE
includes cardiac mortality, myocardial infarction, and stent
thrombosis. BARC ¼ Bleeding Academic Research Consortium;
other abbreviations as in Table 3.
TABLE 5 Independent Predictors of MACE in the Period Between
1 Month and 1 Year Including or Not the PRI Determined
at 1 Month and the SS
OR (95% CI) p Value
Model 1
Age 1.06 (1.02–1.09) 0.001
Diabetes 2.59 (1.27–5.30) 0.009
Model 2
Age 1.06 (1.02–1.09) 0.001
Diabetes 2.52 (1.23–5.19) 0.01
PRI >50% 3.55 (1.61–7.83) 0.002
Model 3
Age 1.04 (1.02–1.08) 0.004
Diabetes 2.37 (1.14–4.93) 0.02
PRI >50% 3.05 (1.37–6.80) 0.006
SS $15 3.78 (1.69–8.42) 0.002
Model 4
Age 1.04 (1.02–1.08) 0.004
Diabetes 2.37 (1.14–4.93) 0.02
SS $15 and PRI >50%* 12.20 (3.48–42.66) <0.0001
SS $15 and PRI #50% 4.21 (1.03–17.16) 0.045
SS <15 and PRI >50% 3.33 (0.82–13.53) 0.10
*The reference group is represented by patients with a PRI #50% and SS <15.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in
Tables 1, 3, and 4.
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1125reclassiﬁcation improvement of 18% and an IDI
of 2.3%.
Finding a trade-off between the risk of
ischemic and bleeding events is a key determinant
for improving the beneﬁt of antiplatelet therapy.
Importantly, our study shows a nonlinear relation-
ship between platelet reactivity and the risk of
ischemic and bleeding events, suggesting that, below
speciﬁc thresholds of PRI, ischemic events are not
further reduced (PRI <51%), whereas the risk of
bleeding is increased (PRI <40%). In view of the
limitations of currently available antiplatelet treat-
ments, ﬁne titration of the antiplatelet therapy with a
consistent effect within a speciﬁc therapeutic win-
dow might therefore reveal a better strategy to opti-
mize the outcomes of patients with NSTEACS
undergoing PCI. These ﬁndings are consistent with
those of previous studies that identiﬁed a therapeutic
window for platelet reactivity using a different assay,
which deﬁned a group of patients with a balanced risk
of ischemic and bleeding events (12).
Also consistent with other studies (12), we observed
a signiﬁcant variability in platelet responsiveness to
clopidogrel across the 1-month period. However, there
was no signiﬁcant difference between PRI measured
at 1 month and PRI measured at hospital discharge
for risk prediction of both MACE and bleeding occur-
ring between 1 month and 1 year. Moreover, HPR and
SS at hospital discharge effectively stratiﬁed thesubsequent risk of MACE up to 1-year follow-up.
Therefore, notwithstanding the variability in platelet
reactivity across the 1-month period in patients
with NSTACS, our ﬁndings suggest that risk stratiﬁ-
cation can be effectively performed also at hospital
discharge using pre-discharge PRI and the SS.
These observations from the GEPRESS study may
be important for the use of the more potent P2Y12
receptor inhibitors. In fact, although both prasugrel
and ticagrelor signiﬁcantly reduce the risk of ischemic
events compared with clopidogrel (21,22), they are
associated with an increased risk of major bleeding.
Moreover, the results of our study showing that HPR
was a predictor of adverse outcomes only among
patients with an SS $15 may explain why previous
trials of tailoring antiplatelet therapies that stratiﬁed
patients only based on HPR did not yield clinical
beneﬁt. Indeed, our study ﬁndings may set the basis
for the design of future randomized trials of tailored
antiplatelet therapy with more potent P2Y12 receptor
inhibitors.
Some studies have reported an association be-
tween genetic variants associated with the clopidog-
rel metabolic pathway and the risk of MACE in
patients undergoing PCI (5), but others have refuted
this association (4). In the GEPRESS study, only
CYP2C19*2 was independently associated with HPR,
but it was not associated with an increased risk of
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does not support the concept of individualizing an-
tiplatelet therapy on the basis of pharmacogenetic
information. This may be explained by the fact that
CYP2C19*2 accounts for only 5% to 12% of the inter-
individual variability of response to clopidogrel (23),
which is affected by several other clinical and
demographic variables. Although this study may be
underpowered to ﬁnd a link between genetic testing
and poor outcomes, it suggests that platelet function
testing may be more sensitive than genetic testing in
predicting the risk of MACE. Platelet function testing
in fact is sensitive to more variables affecting the
response to clopidogrel, and therefore it is closer
to the phenotypic characteristics of the patients.
STUDY LIMITATIONS. The impact of genetic variants
on the risk of MACE was performed in a subgroup of
patients (n ¼ 750), and therefore it may be under-
powered. Lacking external validation, the range of
PRI values suggested to minimize the risk of ischemic
and bleeding events should be interpreted with
caution. Troponin levels were determined at each
interventional site, and therefore some variability
between different assays may exist. Subgroup ana-
lyses were not performed due to insufﬁcient statisti-
cal power. The test for interaction between HPR and
SS was not statistically signiﬁcant. However, the
study did not have sufﬁcient statistical power to
detect such an interaction.CONCLUSIONS
HPR is associated with increased rates of ischemic
events only in patients with a high SS, suggesting a
possible setting in which platelet function testing
could be implemented to optimize antiplatelet ther-
apy. CYP2C19*2 was the only genetic variant signiﬁ-
cantly associated with HPR, but it was not associated
with the risk of MACE.
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